August 18, 2011
BD Diagnostics and Biodiversity Collaborate to Develop Portfolio of Assays on the BD MAX™ System
|
August 03, 2011
BD and Lab21 Collaborate to Develop Aspergillus Assay for New BD MAX™ Molecular Testing System
|
May 19, 2011
BD Launches BD MAX™ System in U.S. to Empower Laboratories and Clinicians to Respond to Emerging Diseases
|
May 09, 2011
BD and Diagenode Collaborate to Expand Infectious Disease Menu on the BD MAX™ System
|
May 06, 2011
BD Launches BD MAX™ Open System in Europe and Reveals Strategy to Build Broad Menu of Assays that Provide Timely, Accurate Information to Laboratories and Clinicians
|
October 25, 2010
BD Diagnostics and Lonza Collaborate to Commercialize the Lonza microCompass™ Molecular Assays on the BD MAX™ System
|
August 03, 2010
BD Receives CLIA "Moderate Complexity" Status for the BD MAX™ GBS Assay
|
July 13, 2010
Study Shows Universal Surveillance for MRSA Significantly Decreased Healthcare-Associated Infections at Pitt County Memorial Hospital
|
June 02, 2010
BD Announces First FDA-Cleared Assay on the BD MAX™ System to Detect Group B Streptococcus
|
December 24, 2009
BD GeneOhm™ MRSA ACP Assay Results in Fewer Steps and Less Hands-On Time for Lab Workers
|
November 19, 2009
BD Completes Acquisition of HandyLab, Inc.
|
October 23, 2009
BD Announces Agreement to Acquire HandyLab, Inc.
|
August 06, 2009
BD Adds Surveillance Capability to Infectious Disease Portfolio
|
August 05, 2009
APIC Announces Launch of Online Education Center for Instant Access to Comprehensive Infection Prevention
|
May 18, 2009
BD and HandyLab Announce Exclusive Collaboration to Commercialize Molecular Assays
|
March 25, 2009
BD Announces Health Canada Licensing of Novel Molecular Assay for the Detection of Vancomycin Resistance Genes
|
January 12, 2009
BD Announces FDA 510(k) Clearance of Novel Molecular Assay to Diagnose Clostridium difficile Infections
|
December 17, 2008
BD Selected to Participate in Premier QUEST Nationwide Hospital Collaborative to Reduce Healthcare-Associated Infections
|
November 20, 2008
BD Announces Health Canada Licensing of Novel Molecular Assay for Detection of Clostridium difficile Toxin B Gene
|
July 07, 2008
BD Announces CE Marking of a New Molecular Test to Diagnose Patients with Clostridium difficile Infections
|
June 10, 2008
BD Celebrates Opening of New Manufacturing Center in Québec
|
April 07, 2008
Preliminary Data from Pitt County Memorial Hospital Study Show Benefit of Active Surveillance on Reducing MRSA VAP Rates in Surgical ICU
|
March 17, 2008
BD GeneOhm™ MRSA Assay Part of Largest U.S. Study Using Universal Active Surveillance to Significantly Reduce MRSA Infection Rates
|
January 02, 2008
BD Announces FDA 510(k) Clearance of Two-Hour Test to Identify Superbug in Patients with Positive Blood Cultures
|
December 20, 2007
BD Announces CE Marking of Rapid Molecular Test to Identify Superbug from Nasal and Wound Specimens
|
December 18, 2007
UCLH Study Demonstrates Rapid Patient Screening Could Cut MRSA Rates By Almost 40 Per Cent
|
November 05, 2007
BD Sponsors New Tool to Combat MRSA Infections in Hospitals
|
October 04, 2007
BD GeneOhm's Flagship Client, Evanston Northwestern Healthcare, Receives Prestigious Patient Safety Award from the NQF and the Joint Commission for its MRSA Prevention Program
|
May 21, 2007
BD Receives CE Mark Approval for Two-Hour Test to Identify Superbug in Patients with Positive Blood Cultures
|
April 25, 2007
BD Announces FDA 510(k) Submission of Two Hour Test to Identify Superbug in Patients with Positive Blood Cultures
|
March 12, 2007
Evanston Northwestern Healthcare Study Reveals Who is Most at Risk for Carrying MRSA (PDF)
|
March 12, 2007
Evanston Northwestern Healthcare Study Shows Benefit of Universal Surveillance (PDF)
|
